Pfizer

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Francisco

Not Invested

Community Contributor

Published

04 Mar 25

n/a

Francisco's Fair Value

n/a

-8.6%

-0.9%

-8.6%

-0.9%

You can edit this narrative until May 14 2:32 AM. Then, changes will post as Updates.

Author's Valuation

US$30.6220.2% undervalued

Francisco's Fair Value

Narrative

Updates0

Francisco'sFair Value

US$30.62

20.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-3.20%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$11.21b

Earnings '28

18.55x

PE Ratio '28

US$208.00b

Market Cap '28

US$208.00b

Market Cap '28

5.67b

No. shares '28

US$36.69

Share Price '28

US$36.69 Share Price '28

Discounted to 2025 @ 6.21% p.a.

US$30.62

Fair Value '25